Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $298
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $275 to $298.
Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $275 to $298.